1-(4-chlorophenyl)-3-(2-furanylmethyl)thiourea is a chemical compound with the following structural formula:
**Structure:**
```
Cl
\\
C6H4 - NH - C(=S) - NH - CH2 - C4H3O
```
**Importance in Research:**
While this specific compound may not have widespread notoriety in research, it's important to understand its potential significance based on its structural features and the broader context of thiourea derivatives.
**Thiourea Derivatives:**
Thiourea derivatives are a class of compounds that often exhibit diverse biological activities, making them attractive targets for research in various fields:
* **Pharmacology:** They are known for their antibacterial, antifungal, antiviral, anti-inflammatory, and anticancer properties.
* **Agriculture:** Some thiourea derivatives act as herbicides and fungicides.
* **Materials Science:** Their unique properties are explored for applications in polymers, dyes, and sensors.
**Possible Importance of 1-(4-chlorophenyl)-3-(2-furanylmethyl)thiourea:**
* **The presence of the 4-chlorophenyl group:** Halogenated aromatic rings are common in pharmaceuticals and can influence biological activity, potentially enhancing binding affinity or stability.
* **The presence of the 2-furanylmethyl group:** Furan derivatives are often found in natural products with biological activity. The 2-furanylmethyl group might contribute to drug-like properties.
* **Thiourea moiety:** This functional group is known for its ability to form hydrogen bonds and interact with biological targets.
**Potential Research Directions:**
* **Biological Activity:** Investigating the compound's potential antibacterial, antifungal, or other biological activities.
* **Pharmacokinetic Studies:** Determining its absorption, distribution, metabolism, and excretion properties in living organisms.
* **Target Identification:** Identifying the specific biological targets that this compound interacts with.
**Note:**
It's crucial to understand that the importance of this specific thiourea derivative remains speculative. Further research and experimental data are needed to confirm its actual properties and potential applications.
ID Source | ID |
---|---|
PubMed CID | 841941 |
CHEMBL ID | 493506 |
CHEBI ID | 107589 |
SCHEMBL ID | 13805297 |
Synonym |
---|
n-(4-chlorophenyl)-n'-(2-furylmethyl)thiourea |
AK-968/41018774 |
MLS000700182 |
smr000227893 |
MAYBRIDGE1_006047 |
STK017245 |
1-(4-chlorophenyl)-3-(furan-2-ylmethyl)thiourea |
CHEBI:107589 |
HMS558K19 |
CHEMBL493506 |
AKOS001636983 |
CCG-65 |
HMS2544E04 |
1-(4-chlorophenyl)-3-(2-furylmethyl)thiourea |
SCHEMBL13805297 |
32564-38-8 |
1-(4-chlorophenyl)-3-(2-furanylmethyl)thiourea |
Q27185914 |
sr-01000465072 |
SR-01000465072-1 |
1-(4-chlorophenyl)-3-[(furan-2-yl)methyl]thiourea |
Class | Description |
---|---|
thioureas | Compounds of general formula RR'NC(=S)NR''R'''. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 21.3313 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 79.4328 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
Smad3 | Homo sapiens (human) | Potency | 0.3162 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 70.7946 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
P53 | Homo sapiens (human) | Potency | 56.2341 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 17.7828 | 0.0018 | 15.6638 | 39.8107 | AID894 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 17.7828 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 14.5015 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 28.1838 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID391677 | Inhibition of DNA dependent DNA polymerase activity of HIV1 BH10 recombinant reverse transcriptase p66/p51 assessed as residual enzyme activity at 50 ug/ml relative to control | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18 | Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1. |
AID391676 | Inhibition of RNA dependent DNA polymerase activity of HIV1 BH10 recombinant reverse transcriptase p66/p51 assessed as residual enzyme activity at 50 ug/ml relative to control | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18 | Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1. |
AID391678 | Antiviral activity against HIV1 infected in human 293T cells assessed as inhibition of pseudovirus infection | 2008 | Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18 | Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |